Catalyst Biosciences Inc (CBIO)

[Frankestin]

Continent is profitable with a robust fibrosis pipeline in various stages of development, including a Phase 3 study of F351 in HBV associated fibrosis and a Phase 2 study poised to initiate in NASH fibrosis.”
The quastion is: 2.5% of that, How much is it worth?

the merger must be voted on!
I wouldn't go short!

So..
The Company's product candidates consist of the coagulation-related assets marzeptacog alfa (activated) (MarzAA), dalcinonacog alfa (DalcA), and CB 2679d-GT.

This agreement will bring to GC Biopharma 3 programs, including "Marzeptacog
alfa (MarzAA)"

if the merger is approved, the loot goes to whoever has the cvr otherwise to everyone...
keep going short LOLOLOL